Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
mi
from
High Point, NC
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
mi
from
High Point, NC
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
mi
from
Cleveland, OH
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated:  12/14/2012
Clinical Research Facility
mi
from
Norfolk, VA
A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients
A Phase II Prospective, Randomized, Double-Masked, Parallel-Group, Multi-centered Study Assessing the Safety and Efficacy of Two Concentrations of DE-101 Ophthalmic Suspension Compared to Placebo for the Treatment of Dry Eye Disease
Status: Enrolling
Updated: 12/14/2012
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 2
Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 2
Status: Enrolling
Updated:  1/3/2013
Contact Alcon Call Center at 1-888-451-3937 for Trial Locations
mi
from
Fort Worth, TX
Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 2
Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 2
Status: Enrolling
Updated: 1/3/2013
Contact Alcon Call Center at 1-888-451-3937 for Trial Locations
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Safety and Efficacy of Adding Azarga Adjunctive to Prostaglandin Therapy
Status: Enrolling
Updated:  1/4/2013
Contact Alcon Call Center
mi
from
Fort Worth, TX
Safety and Efficacy of Adding Azarga Adjunctive to Prostaglandin Therapy
Status: Enrolling
Updated: 1/4/2013
Contact Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Latin America
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
Status: Enrolling
Updated:  1/4/2013
Alcon Call Center
mi
from
Fort Worth, TX
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Latin America
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America
Status: Enrolling
Updated: 1/4/2013
Alcon Call Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
Status: Enrolling
Updated:  1/8/2013
Retinal Consultants of Arizona
mi
from
Phoenix, AZ
Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema
A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
Status: Enrolling
Updated: 1/8/2013
Retinal Consultants of Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated:  1/8/2013
Retinal Consultants of Arizona
mi
from
Phoenix, AZ
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated: 1/8/2013
Retinal Consultants of Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
A Phase 2, Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis® Plus Sirolimus Versus Lucentis® Plus Placebo in Patients With Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated:  1/8/2013
Retinal Consultants of Arizona
mi
from
Phoenix, AZ
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
A Phase 2, Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis® Plus Sirolimus Versus Lucentis® Plus Placebo in Patients With Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status: Enrolling
Updated: 1/8/2013
Retinal Consultants of Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model
Status: Enrolling
Updated:  1/8/2013
Ophthalmic Research Associates
mi
from
Andover, MA
A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model
A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model
Status: Enrolling
Updated: 1/8/2013
Ophthalmic Research Associates
mi
from
Andover, MA
Click here to add this to my saved trials
Sirolimus for Advanced Age-Related Macular Degeneration
Pilot Study of the Evaluation of Intravitreal Sirolimus in the Treatment of Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration
Status: Enrolling
Updated:  1/9/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Sirolimus for Advanced Age-Related Macular Degeneration
Pilot Study of the Evaluation of Intravitreal Sirolimus in the Treatment of Bilateral Geographic Atrophy Associated With Age-Related Macular Degeneration
Status: Enrolling
Updated: 1/9/2013
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated:  1/10/2013
Pfizer Investigational Site
mi
from
Los Angeles, CA
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated: 1/10/2013
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated:  1/10/2013
Pfizer Investigational Site
mi
from
Atlantis, FL
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated: 1/10/2013
Pfizer Investigational Site
mi
from
Atlantis, FL
Click here to add this to my saved trials
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated:  1/10/2013
Pfizer Investigational Site
mi
from
Atlanta, GA
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated: 1/10/2013
Pfizer Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated:  1/10/2013
Pfizer Investigational Site
mi
from
Rochester, NY
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated: 1/10/2013
Pfizer Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated:  1/10/2013
Pfizer Investigational Site
mi
from
Anderson, SC
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated: 1/10/2013
Pfizer Investigational Site
mi
from
Anderson, SC
Click here to add this to my saved trials
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated:  1/10/2013
Pfizer Investigational Site
mi
from
Houston, TX
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
A Phase 1, Double-Masked, Placebo-Controlled Study Evaluating The Safety, Tolerability, Immunogenicity, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Dosages Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration (AMD) Including Geographic Atrophy
Status: Enrolling
Updated: 1/10/2013
Pfizer Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema.
Status: Enrolling
Updated:  1/13/2013
Retina Macula Institute
mi
from
Torrance, CA
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema.
Status: Enrolling
Updated: 1/13/2013
Retina Macula Institute
mi
from
Torrance, CA
Click here to add this to my saved trials
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated:  1/16/2013
Novartis Investigative Site
mi
from
Phoenix, AZ
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated: 1/16/2013
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated:  1/16/2013
Novartis Investigative Site
mi
from
Miami, FL
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated: 1/16/2013
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated:  1/16/2013
Novartis Investigative site
mi
from
Boston, MA
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated: 1/16/2013
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated:  1/16/2013
Novartis Investigative Site
mi
from
Cincinatti, OH
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
Status: Enrolling
Updated: 1/16/2013
Novartis Investigative Site
mi
from
Cincinatti, OH
Click here to add this to my saved trials
Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye
Normative Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for the Measurements of Retinal and RNFL Thickness and Optic Disc Analysis
Status: Enrolling
Updated:  1/16/2013
UC San Diego, Hamilton Glaucoma Center, Department of Ophthalmology
mi
from
La Jolla, CA
Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye
Normative Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for the Measurements of Retinal and RNFL Thickness and Optic Disc Analysis
Status: Enrolling
Updated: 1/16/2013
UC San Diego, Hamilton Glaucoma Center, Department of Ophthalmology
mi
from
La Jolla, CA
Click here to add this to my saved trials
Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye
Normative Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for the Measurements of Retinal and RNFL Thickness and Optic Disc Analysis
Status: Enrolling
Updated:  1/16/2013
USC, Doheny Eye Institute
mi
from
Los Angeles, CA
Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye
Normative Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for the Measurements of Retinal and RNFL Thickness and Optic Disc Analysis
Status: Enrolling
Updated: 1/16/2013
USC, Doheny Eye Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye
Normative Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for the Measurements of Retinal and RNFL Thickness and Optic Disc Analysis
Status: Enrolling
Updated:  1/16/2013
UC Davis, Medical Center, Department of Ophthalmology & Vision Science
mi
from
Sacramento, CA
Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye
Normative Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for the Measurements of Retinal and RNFL Thickness and Optic Disc Analysis
Status: Enrolling
Updated: 1/16/2013
UC Davis, Medical Center, Department of Ophthalmology & Vision Science
mi
from
Sacramento, CA
Click here to add this to my saved trials
Comparative Study of the Optical Biometer for Measurements of the Eye
Comparative Study of the Optical Biometer for the Measurements of Axial Length, Anterior Chamber Depth, Keratometry, Corneal Cylinder Axis, Corneal Thickness, White-to-White Distance, and Pupil Diameter
Status: Enrolling
Updated:  1/16/2013
Physicians Protocol
mi
from
Greensboro, NC
Comparative Study of the Optical Biometer for Measurements of the Eye
Comparative Study of the Optical Biometer for the Measurements of Axial Length, Anterior Chamber Depth, Keratometry, Corneal Cylinder Axis, Corneal Thickness, White-to-White Distance, and Pupil Diameter
Status: Enrolling
Updated: 1/16/2013
Physicians Protocol
mi
from
Greensboro, NC
Click here to add this to my saved trials
Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis
Status: Enrolling
Updated:  1/18/2013
Eye Care Center, Southern Caalifornia College of Optometry
mi
from
Fullerton, CA
Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis
Status: Enrolling
Updated: 1/18/2013
Eye Care Center, Southern Caalifornia College of Optometry
mi
from
Fullerton, CA
Click here to add this to my saved trials
Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis
Status: Enrolling
Updated:  1/18/2013
Eye Car Center, Southern California college of Optometry
mi
from
Fullerton, CA
Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis
Status: Enrolling
Updated: 1/18/2013
Eye Car Center, Southern California college of Optometry
mi
from
Fullerton, CA
Click here to add this to my saved trials
Optical Coherence Tomography in Multiple Sclerosis Patients
Optical Coherence Tomography in Multiple Sclerosis Patients
Status: Enrolling
Updated:  1/19/2013
Cole Eye Institute
mi
from
Cleveland, OH
Optical Coherence Tomography in Multiple Sclerosis Patients
Optical Coherence Tomography in Multiple Sclerosis Patients
Status: Enrolling
Updated: 1/19/2013
Cole Eye Institute
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Retina Associates SW
mi
from
Tucson, AZ
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Retina Associates SW
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
California Retinal Consultants
mi
from
Bakersfield, CA
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
California Retinal Consultants
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Retina-Vitreous Associates
mi
from
Beverly Hilss, CA
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Retina-Vitreous Associates
mi
from
Beverly Hilss, CA
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Colorado Retina
mi
from
Golden, CO
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Colorado Retina
mi
from
Golden, CO
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Florida Eye Microsurgical Institute
mi
from
Boynton Beach, FL
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Florida Eye Microsurgical Institute
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Retina Health Center
mi
from
Fort Myers, FL
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Retina Health Center
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Midwest Eye Institute
mi
from
Indianapolis, IN
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Midwest Eye Institute
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Elman Retina
mi
from
Baltimore, MD
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Elman Retina
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Cumberland Valley Retina Consultants
mi
from
Hagerstown, MD
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Cumberland Valley Retina Consultants
mi
from
Hagerstown, MD
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Ophthalmic Consultants of Boston
mi
from
Boston, MA
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Ophthalmic Consultants of Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Vision Research Foundation
mi
from
Grand Rapids, MI
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Vision Research Foundation
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Vision Research Foundation
mi
from
Royal Oak, MI
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Vision Research Foundation
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Vision Research Foundation
mi
from
Traverse City, MI
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Vision Research Foundation
mi
from
Traverse City, MI
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Total Practice Management
mi
from
New Brunswick, NJ
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Total Practice Management
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Macula Care
mi
from
New York, NY
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Macula Care
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Retina Associates of Cleveland
mi
from
Cleveland, OH
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Retina Associates of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
PA Retina
mi
from
Camp Hill, PA
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
PA Retina
mi
from
Camp Hill, PA
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
TN Retina
mi
from
Nashville, TN
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
TN Retina
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
Medical Center Ophthalmology Associates
mi
from
San Antonio, TX
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
Medical Center Ophthalmology Associates
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated:  1/21/2013
University of Wisconsin
mi
from
Madison, WI
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.
Status: Enrolling
Updated: 1/21/2013
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials